

- [Investor Presentation](#)
- [Events](#)
- [Earnings Calls & Releases](#)
- [SEC Filings](#)
- [Annual Meeting & Reports](#)
- [Corporate Governance](#)
- [Investor Resources](#)



Cardiology

- [Companies](#)
- [Professional Products](#)
- [Disease Areas](#)
- [Cardiology](#)
- [Drugs of Abuse](#)
- [Infectious Disease](#)
- [Oncology](#)
- [Women's Health](#)
- [Brands](#)
- [Health Management](#)
- [Consumer](#)

[Professional Products](#) [Disease Areas](#)

Clearview[®] Simplify D-dimer

Venous thromboembolism (VTE) is a term for a collection of conditions which includes deep vein thrombosis (DVT) and pulmonary embolism (PE).

In most western societies, VTE is a bigger killer than breast cancer, HIV/AIDS, and traffic accidents combined, but if it is diagnosed early and treated appropriately, many deaths are preventable.

Clearview[®] Simplify D-dimer is a rapid, two-step test for the detection of D-dimer, which aids in the diagnosis of DVT and PE. The test works with capillary whole blood, venous whole blood, or plasma samples, making it ideal for point of care use; e.g., in the ER or in clinics. When used in conjunction with a clinical scoring protocol, it can be used as a rule-out test, thus saving money and offering better utilisation of valuable resources.

The test utilises a highly specific monoclonal antibody (3B6/22) for D-dimer, which minimizes the false positive results. The test also has in-built controls that ensure its accuracy and reliability.

To find out more about Clearview[®] Simplify D-dimer:

For North America go to <http://www.invernessmedicalpd.com/>

For all other areas of the world go to <http://www.clearview.com/>